Latest Articles

Publication Date
All News Scientific
Molecular subtype of recurrent implantation failure reveals distinct endometrial etiology of female infertility - Journal of Translational Medicine

Molecular subtype of recurrent implantation failure reveals distinct endometrial etiology of female infertility Journal of Translational Medicine

Published: July 14, 2025, 11:45 a.m.
Read Full Article
BioNTech’s Promising Phase III Trial for Recurrent Endometrial Cancer - TipRanks

BioNTech’s Promising Phase III Trial for Recurrent Endometrial Cancer TipRanks

Published: July 11, 2025, 4:24 p.m.
Read Full Article
Dr Pothuri on Current Unmet Needs in Recurrent/Advanced Endometrial Cancer - OncLive

Dr Pothuri on Current Unmet Needs in Recurrent/Advanced Endometrial Cancer OncLive

Published: July 1, 2025, 4:14 p.m.
Read Full Article
The role of m6A methylation in female reproductive physiology and pathology.

N6-methyladenosine (m6A) is a critical regulator of female reproductive physiology, yet existing reviews have focused predominantly on oocytes. The objective of this review is to systematically evaluate the regulatory effects …

Published: July 1, 2025, midnight
Read Full Article
Endometrial receptivity Female infertility Granulosa cell Immune environment Oocyte m6A methylation
Selinexor Maintenance Displays Durable Benefit in TP53 Wild-Type Advanced/Recurrent Endometrial Cancer - OncLive

Selinexor Maintenance Displays Durable Benefit in TP53 Wild-Type Advanced/Recurrent Endometrial Cancer OncLive

Published: June 25, 2025, 9:58 p.m.
Read Full Article
Dostarlimab + Chemo Beneficial for Advanced, Recurrent Endometrial Cancer - Physician's Weekly

Dostarlimab + Chemo Beneficial for Advanced, Recurrent Endometrial Cancer Physician's Weekly

Published: June 10, 2025, 6:31 a.m.
Read Full Article
Dostarlimab + Chemo Beneficial for Advanced, Recurrent Endometrial Cancer - HealthDay

Dostarlimab + Chemo Beneficial for Advanced, Recurrent Endometrial Cancer HealthDay

Published: June 9, 2025, 2:50 p.m.
Read Full Article
DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer - BioSpace

DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer BioSpace

Published: June 9, 2025, 12:43 p.m.
Read Full Article
DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer | AZN Stock News - GuruFocus

DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer | AZN Stock News GuruFocus

Published: June 9, 2025, 12:18 p.m.
Read Full Article
Biomarker-Driven Decisions: Insights on Selecting Treatments in Advanced and Recurrent Endometrial Cance - OncLive

Biomarker-Driven Decisions: Insights on Selecting Treatments in Advanced and Recurrent Endometrial Cance OncLive

Published: May 19, 2025, 12:21 p.m.
Read Full Article
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!